Home > Dermatology > AAD 2019 > Late-Breakers > Bermekimab – a future treatment for atopic dermatitis?

Bermekimab – a future treatment for atopic dermatitis?

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
AAD 2019

Atopic dermatitis (AD) involves barrier defects of the epidermis as well as skin inflammation and is often characterised by a debilitating itch. The role of interleukin-1 alpha (IL-1⍺) is not yet completely understood. "It is not clear what role IL-1⍺ plays in skin, but it is already an important player in oncology," said Prof. Eric Simpson (Oregon Health & Science University, USA) during his presentation [1].

Upon mechanical skin irritation or keratinocyte rupture, IL-1⍺ is released, leading to migration of leucocytes into the skin with consecutive inflammation. Once released, IL-1⍺ is also thought to induce a potentiation in sensory neurons; thus, contributing to pain and itch. It also provokes matrix metalloproteinases, entailing a breakdown of the skin barrier.

The new anti-IL-1⍺ antibody bermekimab binds to all forms of IL-1⍺ and neutralises it without targeting IL-1ß. A total of 38 patients with moderate-to-severe AD who did not show adequ...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on